|
|
Article: GenoMed Announces ALLHAT Study is Fatally Flawed.
- Article from:
- PR Newswire
- Article date:
- December 18, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GenoMed, Inc -- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics company, announced today that the ALLHAT study published in today's Journal of the American Medical Association has a fatal research flaw.
ALLHAT, an 8 year study funded by the National Institutes of Health at a cost of over $100 million and involving over 40,000 patients, concluded that lowering blood pressure with a thiazide diuretic was just as effective as therapy with lisinopril, an ACE inhibitor. An editorial in the same issue of JAMA by Dr. Lawrence J. Appel admitted that this result was surprising.
...